Clinical Trial Update: Neoadjuvant Axitinib in Locally Advanced Renal Cell Carcinoma (RCC) [Phase 2]

View source ↗

Summary

This update reports Phase 2 results from a neoadjuvant trial of axitinib in locally advanced renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• INLYTA (AXITINIB)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Kidney Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-02-03